"Let's Share the Pain of Lung Cancer Patients": Korea AstraZeneca Holds "Lung Cancer Empathy Campaign"

Korea AstraZeneca announced on November 15 that it held the "Lung Cancer Empathy Campaign" in recognition of November as "Lung Cancer Awareness Month" and November 17 as "World Lung Cancer Day."

Employees of Korea AstraZeneca are experiencing the Lung Cancer Empathy Kit at an in-house experience booth.
[Photo by Korea AstraZeneca]

The Lung Cancer Empathy Campaign is designed to foster understanding of the daily discomforts faced by lung cancer patients and to highlight the importance of early diagnosis and proactive treatment. The program enabled employees of Korea AstraZeneca and medical professionals treating lung cancer to indirectly experience the challenges faced by patients through the Lung Cancer Empathy Kit, thereby supporting patients on their treatment journeys. The kit was created to help users empathize with common daily difficulties experienced by lung cancer patients, such as shortness of breath, numbness in the hands, and dizziness.

From November 7 to 14, employees of Korea AstraZeneca and medical professionals specializing in lung cancer participated in the Lung Cancer Empathy Kit experience. On November 14, an event was held at Korea AstraZeneca's headquarters, where participants shared their impressions of the kit, and a lung cancer specialist provided in-house disease education. This "Lung Cancer Empathy" event featured a variety of programs aimed at raising awareness about lung cancer.

Professor Hong Sookhee, a medical oncologist at Seoul St. Mary's Hospital, who personally experienced the Lung Cancer Empathy Kit and led the disease education session, stated, "Although advances in medical technology and treatments have significantly improved lung cancer survival rates, many patients still suffer from daily discomforts such as shortness of breath and numbness in the hands. These issues are closely linked to quality of life, and through this kit experience, I was able to better understand the difficulties faced by patients. As a lung cancer specialist, I will continue to empathize with my patients and provide the best possible treatment based on their individual conditions." Professor Hong added, "Lung cancer is often diagnosed late because it lacks early symptoms, and it frequently presents with complications such as brain metastasis, making treatment more challenging and prognosis often poor. Early detection and proactive treatment are critical to improving both the quality of life and survival rates for lung cancer patients."

Yang Miseon, Executive Director of the Oncology Business Unit at Korea AstraZeneca, said, "This campaign was designed to directly experience and empathize with the discomforts of lung cancer patients, to deliver a message of support for their treatment journeys, and to reaffirm AstraZeneca's commitment to advancing lung cancer treatment." She continued, "As a member of the Lung Ambition Alliance (LAA), AstraZeneca aims to treat half of the world's lung cancer patients by 2030, and Korea AstraZeneca will also strive to provide a better treatment environment for lung cancer patients."

This content was produced with the assistance of AI translation services.